Floatz logo

Treg Cells

Chronic Myelogenous Leukemia in Blast Crisis

Masonic Cancer Center, University of MinnesotaCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Chronic Myelogenous Leukemia in Blast Crisis cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 2BBB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Imatinib
The University of Hong Kong
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB

View all 50 →

Same molecule, other indications

Treg Cells is also rated in:

myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
60 / 100
View asset →
acute lymphoblastic leukemiaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →